tiprankstipranks
Advertisement
Advertisement
Bioventus reports Q2 EPS 22c, consensus 22c
PremiumThe FlyBioventus reports Q2 EPS 22c, consensus 22c
17d ago
Bioventus backs FY26 adjusted EPS view 75c-79c, consensus 78c
Premium
The Fly
Bioventus backs FY26 adjusted EPS view 75c-79c, consensus 78c
17d ago
Bioventus initiates review of strategic alternatives
Premium
The Fly
Bioventus initiates review of strategic alternatives
17d ago
Bioventus Shareholders Back Directors and Auditor at 2026 Meeting
PremiumCompany AnnouncementsBioventus Shareholders Back Directors and Auditor at 2026 Meeting
3M ago
Analyst Reiterates Buy on Bioventus, Maintains $14 Price Target Despite CMS Reimbursement Headwinds
Premium
Ratings
Analyst Reiterates Buy on Bioventus, Maintains $14 Price Target Despite CMS Reimbursement Headwinds
3M ago
Bioventus Affirms Outlook After FDA Device Reclassification
Premium
Company Announcements
Bioventus Affirms Outlook After FDA Device Reclassification
3M ago
Bioventus initiated with an Outperform at CJS Securities
PremiumThe FlyBioventus initiated with an Outperform at CJS Securities
5M ago
Bioventus Earnings Call Signals Profitable Growth Ahead
Premium
Company Announcements
Bioventus Earnings Call Signals Profitable Growth Ahead
6M ago
Bioventus management to meet with Barrington
Premium
The Fly
Bioventus management to meet with Barrington
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100